Currently, lung cancer is classified into two broad histological subgroups: non-small-cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The distinction between these two categories is important because the treatment options differ substantially. There are different chemotherapeutic regimens for SCLC and NSCLC, and the initial response to chemotherapy is much greater for patients with SCLC than for those with NSCLC \[[@b1-jptm-2016-04-19],[@b2-jptm-2016-04-19]\]. Currently, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are considered the first-line treatment for a subset of *EGFR*-mutated NSCLC patients \[[@b3-jptm-2016-04-19]\]. In many cases, however, acquired resistance emerges within a year \[[@b4-jptm-2016-04-19]\]. Although the secondary T790M mutation has been well-described and reported in up to 60% of resistant samples \[[@b5-jptm-2016-04-19]\], there have been several studies proposing histological transformation from NSCLC to SCLC as another mechanism of EGFR TKI resistance \[[@b2-jptm-2016-04-19],[@b5-jptm-2016-04-19]-[@b12-jptm-2016-04-19]\]. The possible explanation of this phenomenon can be the transformation of NSCLC, mostly adenocarcinoma (ADC), to high-grade neuroendocrine phenotype \[[@b2-jptm-2016-04-19]\]. The other possibility can be the presence of combined histology of NSCLC and SCLC in initial samples and acquisition of different histological areas in second biopsy samples \[[@b2-jptm-2016-04-19]\]. The reports showed that every transformed SCLC tumor sample retained its original *EGFR*-activating mutation \[[@b6-jptm-2016-04-19]-[@b11-jptm-2016-04-19]\], supporting the idea that these were not independent second-primary cancers \[[@b2-jptm-2016-04-19]\]. In addition, many patients with transformed SCLC tumors were female non-smokers \[[@b6-jptm-2016-04-19]-[@b11-jptm-2016-04-19]\], which is different from the typical SCLC patient demographic.

The recent reports of transformation from NSCLC to SCLC evoke questions regarding the origin of SCLC and clinical questions. The rate of transformation to SCLC in TKI resistant tumors varied according to the study \[[@b5-jptm-2016-04-19],[@b6-jptm-2016-04-19],[@b10-jptm-2016-04-19]\]. Furthermore, it is not certain whether transformation to SCLC is exclusively found as a mechanism of TKI resistance in *EGFR*-mutant tumors. Practical questions include whether repeat biopsy is indicated after EGFR TKI resistance develops following treatment initiation, especially since a good response after switching to a SCLC chemotherapy regimen in transformed SCLC tumors has been reported \[[@b12-jptm-2016-04-19]\].

Here, we report six cases of SCLC transformed from pulmonary ADC in a single institute during a 6-year period.

MATERIALS AND METHODS
=====================

Cases
-----

During a 6-year period (2010--2015), there were a total of 2,310 diagnoses of pulmonary ADC in our institute. Of 2,310 patients, 401 patients underwent a second biopsy or resection for recurrent or metastatic tumors. Out of 401 patients, a total of six patients (1.5%) with primary lung ADC showed transformed SCLC morphology in second biopsy. Two experienced pathologists reviewed the histological slides (S.A and J.H). All patients were treated in the Department of Oncology, Samsung Medical Center (Seoul, Korea). Clinical and follow-up data were obtained through a retrospective analysis of the medical records, including age, sex, smoking history, treatment, clinical course and follow-ups. All patients were followed until March 2016 with median follow-up period of 39.2 months. The study was approved by the Institutional Review Board at Samsung Medical Center (2014-14-08610).

*EGFR* mutation test
--------------------

DNA was extracted from sections of formalin-fixed, paraffin-embedded (FFPE) tissue that was also used for histologic diagnosis. Manual microdissection was performed if tumor cell percentages were less than 70% in available samples. Genomic DNA was extracted using Qiagen DNA FFPE Tissue Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. In cases of lung ADC, routine testing for the *EGFR* mutation was performed in the pathology laboratory using peptide nucleic acid--mediated clamping polymerase chain reaction (PCR) mutation detection kit as previously described \[[@b13-jptm-2016-04-19]\], and results were retrieved from electronic medical records. For one SCLC sample, the *EGFR* mutation was detected using targeted sequencing via Illumina HiSeq 2500 (Illumina Inc., San Diego, CA, USA), which was performed for clinical trial enrollment. For the rest of SCLC samples, the *EGFR* mutation was newly evaluated using Cobas test, a real-time PCR test as previously described \[[@b14-jptm-2016-04-19]\]. *EGFR* mutation results were available for all samples except for one that had no residual tumor.

Immunohistochemistry
--------------------

In the current study, we used representative FFPE tissue sections for immunohistochemical staining (IHC). IHC for CD56 and thyroid transcription factor 1 (TTF-1) was performed for SCLC or combined tumors. Staining was performed on 3-μm-thick sections from each case using a biotin-avidin-peroxidase method on a BOND-MAX autostainer (Leica, Wetzlar, Germany) after retrieval with T/E buffer (CD56) or citrate buffer (TTF-1). We used primary antibodies to CD56 (1:200, Novocastra, Newcastle upon Tyne, UK) and TTF-1 (1:100, Dako, Glostrup, Denmark).

RESULTS
=======

Sample information and histologic features
------------------------------------------

Six patients showed transformation from ADC to SCLC. Sample information and pathologic features are summarized in [Table 1](#t1-jptm-2016-04-19){ref-type="table"}. Of the initial samples with diagnosis of ADC, four were obtained using needle biopsy and two were surgically resected specimens. All second biopsies were obtained using needle biopsy. The histology of the six ADCs was acinar (n=4), mixed acinar and papillary (n=1), and mixed acinar and solid (n=1). Of samples that showed transformation to SCLC upon second biopsy, four showed pure SCLC morphology and two showed combined ADC and SCLC morphology. In two cases, ADC components demonstrated acinar morphology ([Fig. 1](#f1-jptm-2016-04-19){ref-type="fig"}). For small cell components, TTF-1 was expressed in four of six cases and CD56 was expressed in all five available cases. CD56 was not expressed in ADC components.

Clinical information and EGFR status
------------------------------------

The clinical information and *EGFR* mutation status of the six patients are summarized in [Table 2](#t2-jptm-2016-04-19){ref-type="table"}. Initial treatments included complete resection and adjuvant chemotherapy for case 1 (cT2NO), palliative chemotherapy for case 2 (cT3N1M1) and case 4 (cT1N0M1), EGFR TKI for case 3 (cT2N3M1), incomplete resection and palliative chemotherapy for case 5 (cT1N0M1), and complete resection for case 6 (cT1NO). The sites of distant metastasis were as follows; brain (cases 2 and 4), pleura (case 3, 4, and 5), bone (case 4), and liver (case 4).

Of the six patients with ADC in initial biopsy, four (cases 1--4) harbored an *EGFR* mutation (L858R mutation, n=1; exon 19 deletion, n=3). All four, along with case 5 who had wild-type *EGFR* but was enrolled in a clinical trial of gefetinib, were treated with EGFR TKIs. Cases 1 and 3 were treated with irressa, and afatinib was also added for case 1. Case 2 was treated with afatinib only, and cases 4 and 5 were treated with gefetinib only. All five patients who underwent TKI treatment were female non-smokers ([Table 2](#t2-jptm-2016-04-19){ref-type="table"}). Despite TKI treatment, all five patients showed disease progression, upon which a second biopsy was performed. The interval between initial biopsy and second biopsy ranged from 5 to 50 months with mean of 25.3 months.

After confirmation of transformation of SCLC on second biopsy, four patients received further treatment. The treatment option for two patients (cases 1 and 3) was switched to etoposide and cisplatin, and one of them (case 3) showed partial response. Case 5 died due to disease progression and the other patients were alive in the short-term follow-up period.

*EGFR* mutation status was compared between initial and second samples, and all pairs showed the same *EGFR* status. The original *EGFR* mutation in cases 1--4 was retained in all transformed SCLC samples, while cases 5 and 6 showed no *EGFR* mutation in transformed SCLC samples.

DISCUSSION
==========

Transformation of NSCLC to SCLC was recently proposed as a mechanism of resistance to TKI therapy \[[@b2-jptm-2016-04-19],[@b6-jptm-2016-04-19]\]. Identification of histologic transformation may be an important factor in determining a patient's treatment plan due to the differences between NSCLC and SCLC. While most reports of transformation of ADC to SCLC were identified in *EGFR* mutant patients related to TKI treatment, it is not certain whether transformation is exclusively related to *EGFR* mutation or EGFR TKI treatment \[[@b10-jptm-2016-04-19]\]. Here, we report six cases of ADC which showed histologic transformation to SCLC over a 6-year period at a single institute. Similar to previous reports, four cases in our series were ADC with *EGFR* activating mutations that underwent TKI treatment and were subsequently found to have SCLC transformation on second biopsy. However, we also identified two additional cases of SCLC transformation that had no *EGFR* mutation, and one of these cases underwent initial TKI treatment.

EGFR TKIs are now being used worldwide for first-line treatment in a subset of lung cancers bearing *EGFR*-activating mutations, and they have demonstrated dramatic therapeutic efficacy \[[@b15-jptm-2016-04-19]\]. However, acquired resistance through multiple mechanisms has become a major problem \[[@b6-jptm-2016-04-19]\]. One of mechanism of resistance to *EGFR* inhibitors is the histological transformation of ADC to SCLC \[[@b6-jptm-2016-04-19]\]. Although the presence of combined ADC and SCLC histology at initial diagnosis is a possibility, genomic sequencing of *EGFR* mutations shows that both the original tumor and transformed SCLC at the time of resistance share the original *EGFR*-activating mutation, thus supporting the conclusion that these were not independent tumors \[[@b6-jptm-2016-04-19]-[@b11-jptm-2016-04-19]\]. However, the small biopsy size represents only a portion of tumors, and SCLC components may become dominant at the time of disease progression. Of the six patients with initially diagnosed with ADC in our report, two were diagnosed using surgically resected samples rather than needle biopsies. For these two cases, the possibility of combined histology at the initial biopsy can be excluded. In case 6, it was difficult to distinguish between SCLC transformation and second primary SCLC considering the early stage of initial ADC.

In our series, two of six cases were *EGFR*--wild-type ADC. This suggests that transformation to SCLC is not unique to tumors bearing *EGFR* mutations, nor does it exclusively result from TKI treatment. Transformation to SCLC is also reported as a mechanism of acquired resistance to crizotinib in *ALK* rearranged lung tumors \[[@b16-jptm-2016-04-19]\]. In addition, transformation to large cell neuroendocrine carcinoma was identified as an acquired resistance mechanism to EGFR TKIs and crizotinib \[[@b17-jptm-2016-04-19],[@b18-jptm-2016-04-19]\]. Recent studies suggest that alveolar type II cells can give rise to both ADC and SCLC \[[@b19-jptm-2016-04-19]\], so *EGFR*-mutant lung cancers derived from alveolar type II cells may have the potential to transform into SCLC during the disease progression \[[@b2-jptm-2016-04-19]\]. In sum, it seems that acquisition of neuroendocrine phenotype, which includes SCLC transformation, can occur in the progression of disease in both *EGFR*-mutant and *EGFR*--wild-type NSCLCs.

Second biopsies are not routinely performed for lung cancer patients when patients showed resistance to TKI treatment. Therefore, the incidence of transformation to SCLC in NSCLCs cannot be accurately calculated. An acquired TKI resistance arising from the histological transformation to SCLC has been reported to be as high as 3% \[[@b5-jptm-2016-04-19]\]. In our institute, the incidence of transformation to SCLC identified in the second biopsy of total ADCs was 1.5%. Recently in our institute, there were two cases of SCLC transformation in *EGFR* mutant ADC during treatment with AZD9291, an oral irreversible EGFR TKI with selectivity for activating *EGFR* mutations and the T790M resistance mutation \[[@b20-jptm-2016-04-19]\]. These cases were not included in this report. In clinical practice, identification of small cell component is important as the treatment option can be switched to etoposide and cisplatin against SCLC \[[@b12-jptm-2016-04-19]\].

In conclusion, we report six cases of lung cancer demonstrating transformation from ADC to SCLC. Four cases were *EGFR*-mutant tumors from female non-smokers who underwent TKI treatment, and the *EGFR* mutation was retained in the transformed SCLC tumors. The other two ADCs were *EGFR*--wild-type, and one of these patients received EGFR TKI treatment. The neuroendocrine phenotype can thus be acquired during ADC disease progression independent of EGFR TKI treatment.
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![Three cases showing transformation from non-small-cell lung cancer to small-cell lung cancer. (A) Initial biopsy of case 3 shows adenocarcinoma. Second biopsy after Iressa treatment, mediastinal lymph node specimen shows small cell carcinoma (B) and tumor cells are strongly positive for CD56 (C). (D) In case 4, second biopsy after gefetinib treatment reveals combined small-cell and adenocarcinoma histology. (E) Adenocarcinoma is identified in the brain tissue of case 2 at the time of initial diagnosis. (F) Second biopsy after afatinib treatment from this patient has combined small-cell and adenocarcinoma histology. (G) CD56 is expressed in the small cell component of the tumor sample.](jptm-2016-04-19f1){#f1-jptm-2016-04-19}

###### 

Sample information and pathologic features of six patients showing transformation from non-small-cell lung cancer to small cell lung cancer

  Case No.   Initial tumor   Sample type   Sample acquisition site   Subtype                Interval between biopsy (mo)   Transformed tumor       Sample type   Sample acquisition site   IHC TTF-1/CD56
  ---------- --------------- ------------- ------------------------- ---------------------- ------------------------------ ----------------------- ------------- ------------------------- -------------------------------------------------------
  1          ADC             Biopsy        Lung                      Acinar                 37                             SCLC                    Biopsy        Celiac LN                 --/+
  2          ADC             Biopsy        Lung, brain               Acinar and papillary   21                             Combined SCLC and ADC   Biopsy        Lung                      --/+^[a](#tfn1-jptm-2016-04-19){ref-type="table-fn"}^
  3          ADC             Biopsy        LN 4                      Acinar                 8                              SCLC                    Biopsy        LN 7                      +/+
  4          ADC             Biopsy        Lung                      Acinar                 5                              Combined SCLC and ADC   Biopsy        Lung (same site)          +/NA
  5          ADC             Resection     Lung                      Acinar                 31                             SCLC                    Biopsy        Pleura                    +/+
  6          ADC             Resection     Lung                      Acinar and solid       50                             SCLC                    Biopsy        Neck LN                   +/+

IHC, immunohistochemistry; TTF-1,thyroid transcription factor; ADC, adenocarcinoma; SCLC, small cell lung cancer; LN, lymph node; NA, not-applicable.

CD56 was positive in only SCLC components.

###### 

Clinical information and *EGFR* status of six patients showing transformation from non-small-cell lung cancer to small cell lung cancer

  Case No.   Sex   Age (yr)   Smoking history (pack years)   Tumor histology in initial sample   Clinical tage   Initial treatment                                  *EGFR* mutation in initial sample   Treatment related to TKI   Duration of TKI treatment before transformation (mo)   Response to TKI   Tumor histology in second biopsy sample   *EGFR* mutation in second biopsy ample   Treatment after second biopsy                                   Progression or recurrance   Death
  ---------- ----- ---------- ------------------------------ ----------------------------------- --------------- -------------------------------------------------- ----------------------------------- -------------------------- ------------------------------------------------------ ----------------- ----------------------------------------- ---------------------------------------- --------------------------------------------------------------- --------------------------- -------------------------------------------------------
  1          F     57         0                              ADC                                 T2N0            Operation, adjuvant CTx (paclitaxel/carboplatin)   L858R                               Irressa, afatinib          10                                                     PD                SCLC                                      L858R                                    CTx (etoposide/cisplatin)                                       F/U loss                    F/U loss
  2          F     54         0                              ADC                                 T3N1M1          CTx (Alimta/cisplatin)                             Del19                               Afatinib                   11                                                     PD                Combined SCLC and ADC                     del19                                    CTx (gemcitabine/cisplatin)                                     PR                          Alive
  3          F     55         0                              ADC                                 T2N3M1          Iressa                                             Del19                               Iressa                     9                                                      PD                SCLC                                      del19                                    CTx (etoposide/cisplatin)                                       PR                          Alive
  4          F     59         0                              ADC                                 T1N0M1          CTx (Alimta/cisplatin)                             Del19                               Gefetinib                  11                                                     PD                Combined SCLC and ADC                     del19                                    Rociletinib                                                     PD                          Alive
  5          F     68         0                              ADC                                 T1N0M1          Operation, palliative CTx (Alimta/cisplatin)       No mutation                         Gefetinib                  2                                                      PD                SCLC                                      No mutation                              No treatment^[a](#tfn2-jptm-2016-04-19){ref-type="table-fn"}^   PD                          Dead^[b](#tfn3-jptm-2016-04-19){ref-type="table-fn"}^
  6          M     67         35                             ADC                                 T1NO            Operation                                          No mutation                         No TKI                     NA                                                     PD                SCLC                                      No mutation                              No treatment^[a](#tfn2-jptm-2016-04-19){ref-type="table-fn"}^   F/U loss                    F/U loss

EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; F, female; ADC, adenocarcinoma; CTx, chemotherapy; PD, progressive disease; SCLC, small cell lung cancer; F/U, follow-up; PR, partial response; M, male; NA, not-applicable.

No further treatment due to poor condition;

Dead due to disease progression.
